A variety of benzo [6,7] cyclohepta [1,2-b] pyridine derivatives have been evaluated for their in vitro anti-proliferative activity against four cancer cell lines such as HeLa (cervical), MIAPACA (pancreatic), MDA-MB-231 (breast) and IMR32 (neuroblastoma). Among tested compounds, a exhibited potent antiproliferative activity against IMR32 with GI50 value less than 0.01 µM and compounds d, l and n exhibited promising anti-proliferative activity against IMR32 with GI50 values 0.1, 0.21 and 0.21 µM, respectively. This is the first report on in vitro anti-proliferative evaluation of benzo [6,7] cyclohepta [1,2-b] pyridine derivatives in addition to anti-inflammatory activity.

Pramipexole dihydrochloride monohydrate is an antiparkinsons agent which is known as dopamine D2 receptor agonist. It is structurally different from the ergot-derived drugs, e.g. bromocriptine or pergolide. Pramipexole is designated chemically as (S)-2-Amino-4, 5, 6, and 7-tetrahydro-6-(propylamino) benzothiazole and has the molecular formula C10H17N3S. It comes under class I of Biopharmaceutical Classification System. The purpose of this study was to develop and evaluate pramipexole dihydrochloride monohydrate extended release tablets by wet granulation method using different proportions of polymers and binder. Pre-formulation studies were done initially and the results were found to be within the limits. All the mentioned batches were prepared and granules were evaluated for pre-compression parameters such as loss on drying, bulk density, tapped density and compressibility index. Tablets were evaluated for weight variation, thickness, hardness, friability; disintegration time and assay were found to be within the limits. In vitro dissolutions were performed with 0.05M 6.8 PH phosphate buffer and effect of various polymers were explored. Final selection of formulation was based on dissolution profile, from dissolution studies formulation 9 showed 80% drug release within 20 hours, so it will be compared with innovator. Similarity and difference factors which revealed that formulation (F 9) containing HPMC K 200, Eudragit L100 and binder are most successful as it exhibited in vitro drug release that matched with innovator product. In vitro drug release profile reveals that with increased concentration of Eudragit L 100. Accelerated stability studies were performed for the optimized batch which indicated that there were no changes in drug content and in vitro dissolution.

Background: It is well-recognized that emotions and emotional disorders may alter the experience of time. Yet relatively little is known about different aspects of psychological time in relation to anxiety. The purpose of the present study was to explore several aspects of temporal processing, including time perspective, prospective and retrospective time estimation, in persons with anxiety symptoms. Methods: A total of 110 individuals with varying degrees of anxiety participated in two studies. They were assigned to two groups (anxiety–control) based on their scores on anxiety measurements. Participants also completed an inventory of time perspective and several time estimation tasks which were analyzed on a group-level. Depressive symptoms were assessed and used as a covariate in the second study. Results: Anxiety was significantly associated with Past Negative and Future Negative time perspectives as measured by the Swedish Zimbardo Time Perspective Inventory (S-ZTPI), even when controlling for the effect of depressive symptoms. No other significant differences were found. Conclusion: Exploring time perspective in persons with anxious symptoms may provide important insights into features of anxiety. These findings may offer new ways of conceptualizing anxiety and provide suggestions for treatment strategies.

The depressive states of the elderly are frequent and difficult to diagnose due mainly to their clinical heterogeneity. One of the reasons for the increase in the rate of suicide in the over 80 years is probably the non-recognition of depressive states. Thymicand affective complaints frequently occur with advancing age and are too often attributed to the consequences of normal aging, which is accompanied by the successive losses that characterize old age.

Meningiomas are by far the most common tumors arising from the meninges. A myriad of aberrant signaling pathways involved with meningioma tumorigenesis, have been discovered. Understanding these disrupted pathways will aid in deciphering the relationship between various genetic changes and their downstream effects on meningioma pathogenesis. An understanding of the genetic and molecular profile of meningioma would provide a valuable first step towards developing more effective treatments for this intracranial tumor. Chromosomes 1, 10, 14, 22, their associated genes, and other potential targets have been linked to meningioma proliferation and progression. It is presumed that through an understanding of these genetic factors, more educated meningioma treatment techniques can be implemented. Future therapies will include combinations of targeted molecular agents including gene therapy, si-RNA mediation, proton therapy, and other approaches as a result of continued progress in the understanding of genetic and biological changes associated with meningiomas. This review provides an overview of the current knowledge of the genetic, signaling and molecular profile of meningioma and possible treatments strategies associated with such profiles.